{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:07:09Z","timestamp":1773173229920,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ygyno.2017.02.014","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T04:00:54Z","timestamp":1486785654000},"page":"9-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial"],"prefix":"10.1016","volume":"145","author":[{"given":"Brandon-Luke L.","family":"Seagle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohreh","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.02.014_bb0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.02.014_bb0010","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG-3016): a randomised, controlled, open-labal trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.02.014_bb0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00280-016-3187-3","article-title":"Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas","volume":"78","author":"Ebata","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2017.02.014_bb0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2011.09.028","article-title":"An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer","volume":"124","author":"Dalton","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.014_bb0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.02.014_bb0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modeling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.ygyno.2017.02.014_bb0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1634\/theoncologist.2013-0322","article-title":"Bevacizumab in treatment of high-risk ovarian cancer: a cost-effectiveness analysis","volume":"19","author":"Chan","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2017.02.014_bb0040","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At what cost does a potential survival advantge of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.014_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40273-015-0337-0","article-title":"Myths and misconceptions of within-cycle correction: a guide for modelers and decision makers","volume":"34","author":"Elbasha","year":"2016","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.ygyno.2017.02.014_bb0050","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/JCO.2007.13.1961","article-title":"Cost-effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"26","author":"Havrilesky","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.014_bb0055","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T14:50:26Z","timestamp":1528987826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817301257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0090825817301257"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}